PExA to Exhibit at the World’s Largest Lung Cancer Congress – WCLC 2025 in Barcelona
PExA today announces that the company will participate as an exhibitor at the World Conference on Lung Cancer (WCLC) in Barcelona, September 6–9, 2025.
For PExA, participating at WCLC marks an important milestone in the company’s strategic focus on lung cancer diagnostics, early detection, and treatment monitoring.
WCLC is the world’s largest meeting dedicated to lung cancer, bringing together around 7,000 delegates from across the globe – including researchers, clinicians, and industry representatives in fields such as oncology, thoracic surgery, pulmonology, diagnostics, and drug development.
PExA’s patented technology enables non-invasive sampling of microscopic particles from the small airways deep in the lungs – the area where many respiratory diseases, including lung cancer, originate. By providing access to proteins, lipids, and RNA fragments directly from the distal airways, the technology opens new possibilities for biomarker discovery, early diagnostics, and the development of more targeted treatments.
– “After participating at major international respiratory congresses such as ERS and ATS, we are now taking a more targeted step by exhibiting at WCLC,” says Tomas Gustafsson, CEO of PExA. “This is the global main arena for lung cancer research, and we look forward to meeting researchers, clinicians, and pharmaceutical companies to discuss how PExA can contribute to advancing the field.”
Visitors can meet the PExA team at Booth #212 during the congress.
More information about WCLC 2025 is available at wclc.iaslc.org.
For further information, please contact:
Tomas Gustafsson, CEO, info@pexa.se
About PExA AB:
PExA AB PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.